GlaxoSmithKline plc (LON:GSK) insider Simon Dingemans acquired 7 shares of the business’s stock in a transaction that occurred on Tuesday, October 11th. The shares were bought at an average price of GBX 1,728 ($21.39) per share, with a total value of £120.96 ($149.70).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1693.9639 on Monday. GlaxoSmithKline plc has a 52 week low of GBX 1,277.25 and a 52 week high of GBX 1,745.56. The stock has a 50 day moving average of GBX 1,650.69 and a 200-day moving average of GBX 1,561.99. The firm’s market cap is GBX 82.34 billion.
The business also recently disclosed a dividend, which was paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th were paid a GBX 19 ($0.24) dividend. The ex-dividend date was Thursday, August 11th. This represents a yield of 1.12%.
Several research analysts recently issued reports on GSK shares. Shore Capital restated a “hold” rating on shares of GlaxoSmithKline plc in a research report on Wednesday, July 27th. Deutsche Bank AG restated a “hold” rating and set a GBX 1,700 ($21.04) price objective on shares of GlaxoSmithKline plc in a research report on Thursday, July 28th. Jefferies Group upgraded GlaxoSmithKline plc to a “buy” rating and lifted their price objective for the stock from GBX 1,650 ($20.42) to GBX 2,000 ($24.75) in a research report on Thursday, July 14th. BNP Paribas reaffirmed a “neutral” rating and issued a GBX 1,430 ($17.70) target price on shares of GlaxoSmithKline plc in a research note on Sunday, July 3rd. Finally, Independent Research GmbH set a GBX 1,800 ($22.28) target price on shares of GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Thursday, August 4th. Three analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of GBX 1,687.13 ($20.88).
About GlaxoSmithKline plc
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.